Dianthus Therapeutics (NASDAQ:DNTH) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a research report report published on Monday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($1.14) EPS, FY2024 earnings at ($3.06) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.

Other research analysts have also recently issued research reports about the stock. Robert W. Baird began coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target on the stock. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Raymond James lifted their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Oppenheimer lifted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday. Finally, Wedbush reduced their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $25.49 on Monday. Dianthus Therapeutics has a 1 year low of $6.58 and a 1 year high of $33.77. The stock’s fifty day moving average price is $27.65 and its 200-day moving average price is $26.63.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. On average, sell-side analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently made changes to their positions in DNTH. Bain Capital Life Sciences Investors LLC purchased a new position in Dianthus Therapeutics during the 1st quarter valued at approximately $89,761,000. RA Capital Management L.P. purchased a new position in shares of Dianthus Therapeutics in the first quarter valued at $69,990,000. Vanguard Group Inc. increased its position in Dianthus Therapeutics by 250.0% in the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after purchasing an additional 384,182 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Dianthus Therapeutics during the first quarter valued at $11,251,000. Finally, Great Point Partners LLC grew its stake in shares of Dianthus Therapeutics by 21.3% in the 2nd quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after buying an additional 132,929 shares in the last quarter. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.